Anhui Fengyuan Pharmaceutical Co Ltd

The company's capital structure is characterized by a debt-to-equity ratio of 0.48, indicating a moderate reliance on debt financing. Its liquidity position is assessed as medium, with a current ratio of 0.94, suggesting limited short-term liquidity cushion. The price-to-book ratio of 1.37 and price-to-tangible-book ratio of 1.37 indicate that the company's market value is slightly above its book value. The enterprise value to EBITDA ratio of 52.96 and enterprise value to revenue ratio of 3.04 suggest a high valuation relative to earnings and revenue.

Profitability metrics show a return on equity of 2.73% and a return on assets of 1.13%, both of which are below the industry median for pharmaceutical companies. The company's gross profit margin is 20.42% (242,368,860 / 1,187,207,460), and its operating margin is 5.74% (68,140,290 / 1,187,207,460), both of which are below the industry median. The net profit margin is 4.48% (53,201,640 / 1,187,207,460), also below the industry median.

The company's revenue is concentrated in a single geographic region, with all revenue generated in China. There is no disclosed segmental breakdown of revenue, making it difficult to assess the contribution of different product lines or therapeutic areas. The company's exposure to a single market increases its vulnerability to regulatory, economic, and geopolitical risks in China.

The company's revenue growth trajectory is not clearly defined, as there is no historical revenue data provided for comparison. The company's operating cash flow is positive at 32,511,790 CNY, but its capital expenditure is negative at -73,691,790 CNY, indicating that the company is not investing in new projects or capacity. The company's net cash position is negative after subtracting total debt, which is a key flag in the risk assessment.

The company's risk assessment indicates a medium liquidity risk and a low dilution risk. The company has not issued additional shares in the recent period, as the number of basic and diluted shares outstanding is the same. The company's capital structure is stable, with a low probability of near-term dilution. However, the company's negative net cash position and high valuation multiples suggest that it may face challenges in maintaining its current capital structure.

There are no recent events or filings disclosed in the provided data that would indicate significant changes in the company's operations or financial position. The company's financial performance and risk profile are based on the latest available data, and there is no indication of material developments in the near term.

Anhui Fengyuan Pharmaceutical Co Ltd (000153.SZ) has undergone a formal classification update, with its economic sector now explicitly identified as Healthcare and its primary activity defined as Pharmaceuticals. This structural clarification, marked as a medium-severity change, establishes the company’s operational identity within the broader market taxonomy, providing a clearer framework for sector-specific analysis. Concurrently, the company’s risk profile has been initialized with specific assessments. Dilution risk is now classified as low, indicating a stable capital structure with minimal immediate threat of share value erosion from new issuances. This assessment offers reassurance to stakeholders regarding the preservation of existing equity value. In contrast, liquidity risk has been assessed at a medium level. This designation suggests that while the company maintains operational viability, there may be moderate constraints or volatility in its ability to meet short-term financial obligations or trade volume expectations. Investors should monitor this metric as a key indicator of financial flexibility. These updates occur against a backdrop of limited external coverage, as the company currently reports zero analyst counts, index memberships, and top holder records. The absence of these traditional market signals underscores the importance of the newly established internal risk and taxonomy metrics as primary data points for evaluating Anhui Fengyuan’s current standing.

Net margin of 4.5% outperforms the industry median of 3.9%, suggesting superior bottom-line profitability relative to competitors.

Dilution risk is assessed as low, providing some protection for existing shareholders against equity value erosion.

The company faces high credit risk, raising concerns about its ability to meet financial obligations and service debt.

Revenue declined 10.0% year-over-year to CNY 3.86 billion, reflecting weakening top-line growth momentum.

Revenue ¥3.50B; Operating income ¥146.4M.

• ▍Revenue ¥3.50B
• ▍Operating income ¥146.4M
• ▍Net margin 3.3%